Application of antibody-drug conjugates in colorectal cancer
Abstract
Colorectal cancer (CRC) remains a leading cause of cancer incidence and mortality worldwide, and metastatic disease responds poorly to conventional surgery, chemotherapy, and targeted therapy. Antibody-drug conjugates (ADCs) link monoclonal antibodies to cytotoxic payloads through chemical linkers, enabling antigen-specific delivery, intracellular payload release, bystander killing, and Fc-mediated immune effects. ADC efficacy and safety depend on target antigen selection, antibody design, payload choice, linker stability, and internalization efficiency. This narrative review, based on literature and trial data available up to February 2026, summarizes the CRC treatment landscape, ADC mechanisms and component optimization, and clinical progress of ADCs targeting HER2, HER3, TROP-2, CEACAM5, and c-MET. No ADC has been approved specifically for CRC; trastuzumab deruxtecan has tumor-agnostic accelerated approval for HER2 IHC 3+ solid tumors and may cover eligible patients with metastatic CRC. Early trials show promising activity but substantial hematologic, gastrointestinal, hepatic, and interstitial lung disease toxicity, reflecting a narrow therapeutic window. We discuss challenges including target specificity, off-target toxicity, drug resistance, and linker stability, and outline future directions such as probody-drug conjugates, bispecific and dual-payload ADCs, novel payloads, and bioorthogonal linkers to support precision therapy for CRC.
Related
- Antibody–drug conjugates in colorectal cancer: target biology, resistance, and the clinical-trial landscape
- Efficacy and safety of antibody-drug conjugates in advanced small cell lung cancer: a systematic review and single-arm meta-analysis of prospective clinical trials
- Efficacy and safety of antibody-drug conjugates in pretreated HER2-positive advanced breast cancer: a network meta-analysis of randomized controlled trials
- Emerging antibody–drug conjugates in lung cancer: highlights from the 2026 ASCO Annual Meeting
- Combination of antibody–drug conjugates with immunotherapy: a new paradigm in cancer treatment
BibTeX
@article{cai2026application,
title = {{Application of antibody-drug conjugates in colorectal cancer}},
author = {Huazhong Cai and Jingzhe Li and Qiang Cai and Ying Liu and Pan Huang},
journal = {Frontiers in Oncology},
year = {2026},
month = nov,
doi = {10.3389/fonc.2026.2011302},
url = {https://www.frontiersin.org/articles/10.3389/fonc.2026.2011302},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Application of antibody-drug conjugates in colorectal cancer
AU - Huazhong Cai
AU - Jingzhe Li
AU - Qiang Cai
AU - Ying Liu
AU - Pan Huang
PY - 2026
DA - 2026/11/13
JO - Frontiers in Oncology
DO - 10.3389/fonc.2026.2011302
UR - https://www.frontiersin.org/articles/10.3389/fonc.2026.2011302
AB - Colorectal cancer (CRC) remains a leading cause of cancer incidence and mortality worldwide, and metastatic disease responds poorly to conventional surgery, chemotherapy, and targeted therapy. Antibody-drug conjugates (ADCs) link monoclonal antibodies to cytotoxic payloads through chemical linkers, enabling antigen-specific delivery, intracellular payload release, bystander killing, and Fc-mediated immune effects. ADC efficacy and safety depend on target antigen selection, antibody design, payload choice, linker stability, and internalization efficiency. This narrative review, based on literature and trial data available up to February 2026, summarizes the CRC treatment landscape, ADC mechanisms and component optimization, and clinical progress of ADCs targeting HER2, HER3, TROP-2, CEACAM5, and c-MET. No ADC has been approved specifically for CRC; trastuzumab deruxtecan has tumor-agnostic accelerated approval for HER2 IHC 3+ solid tumors and may cover eligible patients with metastatic CRC. Early trials show promising activity but substantial hematologic, gastrointestinal, hepatic, and interstitial lung disease toxicity, reflecting a narrow therapeutic window. We discuss challenges including target specificity, off-target toxicity, drug resistance, and linker stability, and outline future directions such as probody-drug conjugates, bispecific and dual-payload ADCs, novel payloads, and bioorthogonal linkers to support precision therapy for CRC.
SN - 2234-943X
ER -